0001493152-22-017739.txt : 20220624 0001493152-22-017739.hdr.sgml : 20220624 20220624171707 ACCESSION NUMBER: 0001493152-22-017739 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220624 DATE AS OF CHANGE: 20220624 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Greenwich LifeSciences, Inc. CENTRAL INDEX KEY: 0001799788 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205473709 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39555 FILM NUMBER: 221040934 BUSINESS ADDRESS: STREET 1: 3992 BLUEBONNET DR, BUILDING 14 CITY: STAFFORD STATE: TX ZIP: 77477 BUSINESS PHONE: 203-434-3290 MAIL ADDRESS: STREET 1: 3992 BLUEBONNET DR, BUILDING 14 CITY: STAFFORD STATE: TX ZIP: 77477 10-K/A 1 form10-ka.htm
0001799788 true FY GLSI --12-31 0001799788 2021-01-01 2021-12-31 0001799788 2021-06-30 0001799788 2022-03-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-K/A

(Amendment No. 1)

(Mark One)

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Transition Period from                      to

 

Commission File Number: 001-39555

 

GREENWICH LIFESCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   20-5473709

(State or other jurisdiction

of incorporation or organization)

  

(I.R.S. Employer

Identification No.)

     
3992 Bluebonnet Dr., Building 14, Stafford, Texas 77477   77477
(Address of principal executive offices)   (Zip Code)

 

(832) 819-3232

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Name of each exchange on which registered
Common Stock, $0.001 par value   The NASDAQ Capital Market

 

Auditor Firm ID   Auditor Name   Auditor Location
206   MaloneBailey, LLP   Houston, Texas

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐   Non-accelerated filer ☒   Smaller reporting company ☒   Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates based on a closing sale price of $44.94 per share, which was the last sale price of the common stock as of June 30, 2021, the last business day of the registrant’s most recently completed second fiscal quarter, was $171,492,883.

 

As of March 21, 2022, 12,951,453 shares of the registrant’s common stock, $0.001 par value per share, were issued and outstanding.

 

 

 

 
 

 

EXPLANATORY NOTE

 

This Amendment No. 1 (the “Amendment No. 1”) to the Annual Report on Form 10-K/A of Greenwich LifeSciences, Inc. (the “Company”) for the fiscal year ended December 31, 2021, originally filed with the Securities and Exchange Commission (the “SEC”) on March 21, 2022 (the “Original Filing”) is being filed solely to include an amended Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters to include a 5% or more stockholder who was inadvertently omitted.

 

This Amendment No. 1 contains only the cover page, this explanatory note, Item 12 and the revised certifications. Because no financial statements have been included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. We are not including the certifications under Section 906 of the Sarbanes-Oxley Act of 2002 as no financial statements are being filed with this Amendment No. 1.

 

Except for the foregoing, this Amendment No. 1 does not alter or update any information contained in the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with the Company’s filings made with the SEC subsequent to the filing of the Original Filing.

 

- 2 -
 

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The following table sets forth certain information regarding the beneficial ownership of our common stock as of March 21, 2022 by:

 

  ● each of our named executive officers;
     
  ● each of our directors;
     
  ● all of our current directors and executive officers as a group; and
     
  ● each stockholder known by us to own beneficially more than 5% of our common stock.

 

Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. Shares of common stock that may be acquired by an individual or group within 60 days of March 21, 2022, pursuant to the exercise of options or warrants, vesting of common stock or conversion of preferred stock or convertible debt, are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Percentage of ownership is based on 12,951,453 shares of common stock issued and outstanding as of March 21, 2022.

 

Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of common stock shown to be beneficially owned by them, based on information provided to us by such stockholders. Unless otherwise indicated, the address for each director and executive officer listed is: c/o Greenwich LifeSciences, Inc., 3992 Bluebonnet Dr, Building 14, Stafford, TX 77477.

 

- 3 -
 

 

    Number of Shares     Percentage of Common Stock  
Name of Beneficial Owner   Beneficially Owned     Beneficially Owned  
Directors and Named Executive Officers                
Snehal Patel     5,075,225 (1)     39.08 %
F. Joseph Daugherty     81,849 (2)     *  
David McWilliams     617,203 (3)     4.76 %
Eric Rothe     311,171 (4)     2.40 %
Kenneth Hallock     395,249 (5)     3.05 %
All current named executive officers and directors as a group (5 persons)     6,480,697       49.87 %
5% or Greater Stockholders                
Michael Weiner     3,149,026 (6)     24.31 %

  

* Represents beneficial ownership of less than 1%.
   
(1) Consists of (i) 1,095,708 shares of common stock owned by Snehal Patel, (ii) 1,408,033 shares of common stock owned by Snehal Patel IRA, (iii) 919,234 shares of common stock owned by Patel Family Trust 1, (iv) 743,218 shares of common stock owned by Patel Family Trust 2, (v) 743,218 shares of common stock owned by Patel Family Trust 3, and (vi) 129,400 shares of common stock owned by Kinnary Patel IRA. Excludes 72,807 shares of common stock held by Snehal Patel which vest in 4 equal monthly installments. Snehal Patel and Kinnary Patel, the spouse of Snehal Patel, are the Trustees of the Patel Family Trust 1, Patel Family Trust 2 and Patel Family Trust 3. Snehal Patel is the Trustee of the Snehal Patel IRA. Kinnary Patel is the Trustee of the Kinnary Patel IRA. In such capacities, Snehal Patel is deemed to hold voting and dispositive power over the securities held by such entities.
   
(2) Excludes 7,272 shares of common stock which vest in 4 equal monthly installments.
   
(3) Excludes 10,401 shares of common stock which vest in 4 equal installments.
   
(4) Excludes 2,055 shares of common stock which vest in 4 equal monthly installments.
   
(5) Excludes 2,055 shares of common stock which vest in 4 equal monthly installments. Kenneth Hallock and Annette Hallock are the Trustees of the Hallock Trust and in such capacities share voting and dispositive power over the securities held by such entity.
   
(6) Consists of (i) 161,315 shares of common stock owned by the Yosajo MA Trust 1, (ii) 161,351 shares of common stock owned by the Yosajo MA Trust 2, (iii) 161,317 shares of common stock owned by the Yosajo MI Trust 3, (iv) 663,816 shares of common stock owned by the WLUFMI Trust 1, (v) 663,840 shares of common stock owned by the WLUFMI Trust 2, (vi) 668,714 shares of common stock owned by the WLUFMA Trust 1 and (vii) 668,673 shares of common stock owned by the WLUFMA Trust 2. Michael Weiner is the Trustee of the Yosajo MA Trust 1, Yosajo MA Trust 2, Yosajo MI Trust 3, WLUFMI Trust 1, WLIFMI Trust 2, WLUFMA Trust 1 and WLUFMA Trust 2. In such capacities, Michael Weiner is deemed to hold voting and dispositive power over the securities held by such entities.

 

- 4 -
 

 

PART IV

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 

Exhibit

Number

   Description of Exhibit
    (a)(1) Financial Statements
    The financial statements required by this item are submitted in a separate section beginning on page F-1 of this Annual Report on Form 10-K.

 

(b) Exhibits

 

Exhibit

Number

   Description
3.1   Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Form 8-K filed on October 1, 2020)
3.2   Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Form 8-K filed on October 1, 2020)
4.1   Form of Underwriter Warrant (incorporated by reference to Exhibit 4.2 to Amendment No. 1 to Form S-1 filed on June 23, 2020)
4.2   Description of the Registrant’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.2 to Form 10-K filed on March 31, 2021).
10.1+   2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to Form S-1 filed on May 29, 2020)
10.2   Form of Indemnification Agreement with directors and executive officers (incorporated by reference to Exhibit 10.1 to Form S-1 filed on May 29, 2020)
10.3   Exclusive License Agreement between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and the Company (incorporated by reference to Exhibit 10.3 to Amendment No. 1 to Form S-1 filed on June 23, 2020)
10.4   First Amendment to Exclusive License Agreement between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and the Company (incorporated by reference to Exhibit 10.4 to Amendment No. 1 to Form S-1 filed on June 23, 2020)
10.5   Second Amendment to Exclusive License Agreement between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and the Company (incorporated by reference to Exhibit 10.5 to Amendment No. 1 to Form S-1 filed on June 23, 2020)
10.6   American Arbitration Association Award of Arbitrators (incorporated by reference to Exhibit 10.6 to Amendment No. 1 to Form S-1 filed on June 23, 2020)
10.7+   Employment Agreement between the Company and Snehal Patel dated September 29, 2020 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on October 1, 2020)
10.8   Registration Rights Agreement (incorporated by reference to Exhibit 10.8 to Amendment No. 1 to Form S-1 filed on June 23, 2020)
24**   Power of Attorney (included on signature page hereto).
31.1*   Certification of Principal Executive Officer and Principal Financial Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.
32.1**   Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*   Inline XBRL Instance Document.
101.SCH*   Inline XBRL Taxonomy Extension Schema.
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase.
101.LAB*   Inline XBRL Taxonomy Extension Labels Linkbase.
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase.
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith

** Previously filed

 

+ Indicates a management contract or compensatory plan or arrangement.

 

- 5 -
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  GREENWICH LIFESCIENCES, INC.
   
  /s/ Snehal Patel
June 24, 2022 Chief Executive Officer (Principal Executive Officer and Principal Accounting and Financial Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

SIGNATURE   TITLE   DATE
         
/s/ Snehal Patel   Chief Executive Officer and Director   June 24, 2022
Snehal Patel   (Principal Executive Officer and Principal Accounting and Financial Officer)    
         
*   Chief Medical Officer and Director   June 24, 2022
F. Joseph Daugherty        
         
*   Director   June 24, 2022
David McWilliams        
         
*   Director   June 24, 2022
Eric Rothe        
         
*   Director   June 24, 2022
Kenneth Hallock        

 

*By: /s/ Snehal Patel  
  Attorney-in-Fact  

 

- 6 -

 

 EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

Certification of Chief Executive Officer of Greenwich LifeSciences, Inc.

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Snehal Patel, certify that:

 

  1. I have reviewed this annual report on Form 10-K/A of Greenwich LifeSciences, Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

Date: June 24, 2022 /s/ Snehal Patel
  Snehal Patel
  Chief Executive Officer
  (Principal Executive Officer and Principal Accounting and Financial Officer)

 

 

 EX-101.SCH 3 glsi-20211231.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 glsi-20211231_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Auditor Firm ID Auditor Name Auditor Location EX-101.PRE 5 glsi-20211231_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover - USD ($)
 12 Months Ended
Dec. 31, 2021
Mar. 21, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Amendment Description This Amendment No. 1 (the “Amendment No. 1”) to the Annual Report on Form 10-K/A of Greenwich LifeSciences, Inc. (the “Company”) for the fiscal year ended December 31, 2021, originally filed with the Securities and Exchange Commission (the “SEC”) on March 21, 2022 (the “Original Filing”) is being filed solely to include an amended Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters to include a 5% or more stockholder who was inadvertently omitted.    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Current Fiscal Year End Date --12-31    
Entity File Number 001-39555    
Entity Registrant Name GREENWICH LIFESCIENCES, INC.    
Entity Central Index Key 0001799788    
Entity Tax Identification Number 20-5473709    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 3992 Bluebonnet Dr.    
Entity Address, Address Line Two Building 14    
Entity Address, City or Town Stafford    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 77477    
City Area Code (832)    
Local Phone Number 819-3232    
Title of 12(b) Security Common Stock    
Trading Symbol GLSI    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 171,492,883
Entity Common Stock, Shares Outstanding   12,951,453  
Auditor Firm ID 206    
Auditor Name MaloneBailey, LLP    
Auditor Location Houston, Texas    
XML 7 form10-ka_htm.xml IDEA: XBRL DOCUMENT 0001799788 2021-01-01 2021-12-31 0001799788 2021-06-30 0001799788 2022-03-21 iso4217:USD shares iso4217:USD shares 0001799788 true FY GLSI --12-31 10-K/A true 2021-12-31 2021 false 001-39555 GREENWICH LIFESCIENCES, INC. DE 20-5473709 3992 Bluebonnet Dr. Building 14 Stafford TX 77477 77477 (832) 819-3232 Common Stock NASDAQ 206 MaloneBailey, LLP Houston, Texas No No Yes Yes Non-accelerated Filer true true false false 171492883 12951453 This Amendment No. 1 (the “Amendment No. 1”) to the Annual Report on Form 10-K/A of Greenwich LifeSciences, Inc. (the “Company”) for the fiscal year ended December 31, 2021, originally filed with the Securities and Exchange Commission (the “SEC”) on March 21, 2022 (the “Original Filing”) is being filed solely to include an amended Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters to include a 5% or more stockholder who was inadvertently omitted. EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 3 38 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://greenwichlifesciences.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form10-ka.htm ex31-1.htm glsi-20211231.xsd glsi-20211231_lab.xml glsi-20211231_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-ka.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 3, "dts": { "inline": { "local": [ "form10-ka.htm" ] }, "labelLink": { "local": [ "glsi-20211231_lab.xml" ] }, "presentationLink": { "local": [ "glsi-20211231_pre.xml" ] }, "schema": { "local": [ "glsi-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 62, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 5, "total": 5 }, "keyCustom": 0, "keyStandard": 38, "memberCustom": 0, "memberStandard": 0, "nsprefix": "GLSI", "nsuri": "http://greenwichlifesciences.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://greenwichlifesciences.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://greenwichlifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-017739-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-017739-xbrl.zip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end